Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 16 studies | 32% ± 16% | |
| astrocyte | 12 studies | 36% ± 16% | |
| glutamatergic neuron | 11 studies | 49% ± 23% | |
| GABAergic neuron | 10 studies | 45% ± 22% | |
| epithelial cell | 10 studies | 35% ± 17% | |
| oligodendrocyte precursor cell | 10 studies | 39% ± 17% | |
| oligodendrocyte | 10 studies | 35% ± 13% | |
| fibroblast | 9 studies | 26% ± 10% | |
| adipocyte | 9 studies | 31% ± 8% | |
| microglial cell | 8 studies | 28% ± 10% | |
| amacrine cell | 7 studies | 32% ± 7% | |
| type I pneumocyte | 6 studies | 26% ± 10% | |
| neuron | 6 studies | 44% ± 16% | |
| interneuron | 6 studies | 58% ± 22% | |
| macrophage | 6 studies | 32% ± 9% | |
| pericyte | 6 studies | 33% ± 13% | |
| retina horizontal cell | 6 studies | 30% ± 11% | |
| natural killer cell | 5 studies | 20% ± 3% | |
| B cell | 5 studies | 21% ± 5% | |
| cardiac muscle cell | 5 studies | 43% ± 13% | |
| ciliated cell | 5 studies | 24% ± 6% | |
| basal cell | 5 studies | 32% ± 20% | |
| endothelial cell of lymphatic vessel | 5 studies | 29% ± 9% | |
| goblet cell | 5 studies | 37% ± 25% | |
| club cell | 5 studies | 23% ± 6% | |
| smooth muscle cell | 5 studies | 24% ± 5% | |
| CD4-positive, alpha-beta T cell | 4 studies | 18% ± 2% | |
| retinal bipolar neuron | 4 studies | 30% ± 7% | |
| granule cell | 4 studies | 35% ± 10% | |
| retinal ganglion cell | 4 studies | 24% ± 10% | |
| retinal cone cell | 4 studies | 22% ± 3% | |
| retinal rod cell | 4 studies | 18% ± 2% | |
| lymphocyte | 4 studies | 26% ± 9% | |
| Mueller cell | 4 studies | 22% ± 7% | |
| type B pancreatic cell | 3 studies | 33% ± 14% | |
| effector memory CD8-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
| GABAergic interneuron | 3 studies | 44% ± 5% | |
| retinal pigment epithelial cell | 3 studies | 37% ± 25% | |
| GABAergic amacrine cell | 3 studies | 31% ± 9% | |
| OFF-bipolar cell | 3 studies | 28% ± 3% | |
| ON-bipolar cell | 3 studies | 31% ± 5% | |
| glycinergic amacrine cell | 3 studies | 30% ± 4% | |
| rod bipolar cell | 3 studies | 42% ± 6% | |
| dendritic cell | 3 studies | 34% ± 18% | |
| respiratory goblet cell | 3 studies | 20% ± 2% | |
| CD8-positive, alpha-beta T cell | 3 studies | 16% ± 1% | |
| hepatocyte | 3 studies | 41% ± 15% | |
| pancreatic A cell | 3 studies | 28% ± 9% | |
| ependymal cell | 3 studies | 36% ± 14% | |
| enteroendocrine cell | 3 studies | 20% ± 4% | |
| type II pneumocyte | 3 studies | 23% ± 6% | |
| brush cell | 3 studies | 19% ± 4% | |
| mast cell | 3 studies | 22% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 1516.94 | 245 / 245 | 100% | 10.86 | 501 / 502 |
| brain | 100% | 1257.71 | 2632 / 2642 | 100% | 10.39 | 704 / 705 |
| ovary | 100% | 1417.42 | 180 / 180 | 99% | 9.64 | 427 / 430 |
| thymus | 100% | 1326.60 | 653 / 653 | 99% | 8.91 | 596 / 605 |
| breast | 100% | 1142.59 | 459 / 459 | 98% | 16.47 | 1092 / 1118 |
| intestine | 100% | 1467.86 | 966 / 966 | 96% | 7.55 | 504 / 527 |
| stomach | 100% | 804.48 | 359 / 359 | 95% | 8.54 | 271 / 286 |
| kidney | 100% | 919.04 | 89 / 89 | 94% | 6.66 | 851 / 901 |
| adrenal gland | 100% | 955.81 | 258 / 258 | 94% | 6.04 | 217 / 230 |
| pancreas | 100% | 628.18 | 327 / 328 | 94% | 9.17 | 167 / 178 |
| bladder | 100% | 1181.71 | 21 / 21 | 91% | 7.65 | 460 / 504 |
| lung | 100% | 960.86 | 577 / 578 | 86% | 6.59 | 996 / 1155 |
| esophagus | 100% | 946.28 | 1445 / 1445 | 85% | 8.34 | 155 / 183 |
| skin | 100% | 1070.75 | 1808 / 1809 | 69% | 3.27 | 328 / 472 |
| liver | 100% | 600.68 | 225 / 226 | 68% | 2.93 | 276 / 406 |
| uterus | 100% | 1404.45 | 170 / 170 | 57% | 3.70 | 261 / 459 |
| adipose | 100% | 844.26 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1053.92 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 4.38 | 1 / 1 |
| blood vessel | 100% | 939.06 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 100% | 714.08 | 801 / 803 | 0% | 0 | 0 / 0 |
| heart | 97% | 843.01 | 838 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 86% | 4.41 | 25 / 29 |
| eye | 0% | 0 | 0 / 0 | 51% | 2.15 | 41 / 80 |
| peripheral blood | 33% | 328.97 | 304 / 929 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 27% | 0.85 | 12 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0010526 | Biological process | retrotransposon silencing |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0005634 | Cellular component | nucleus |
| GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
| GO_0003700 | Molecular function | DNA-binding transcription factor activity |
| GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
| GO_0008270 | Molecular function | zinc ion binding |
| Gene name | ZNF91 |
| Protein name | Zinc finger protein 91 Zinc finger protein 91 (Zinc finger protein HPF7) (Zinc finger protein HTF10) |
| Synonyms | |
| Description | FUNCTION: Transcription factor specifically required to repress SINE-VNTR-Alu (SVA) retrotransposons: recognizes and binds SVA sequences and represses their expression by recruiting a repressive complex containing TRIM28/KAP1 . May also bind the promoter of the FCGR2B gene, leading to repress its expression; however, additional evidence is required to confirm this result in vivo . . |
| Accessions | ENST00000595533.1 Q05481 ENST00000397082.2 [Q05481-2] M0R186 ENST00000599743.5 ENST00000300619.12 [Q05481-1] M0QX31 |